Markets:

Overview

News

Currencies

International

Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.420 -0.090 (-2.57%)

Streaming Delayed Price Updated: 3:29 PM EDT, Mar 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

When You Buy Nvidia Stock, You Get a Bonus: An Artificial Intelligence (AI) ETF of Sorts ↗

September 03, 2025

Nvidia's six-stock portfolio of publicly traded AI stocks was worth $4.3 billion at the end of the second quarter, and the company also owns stakes in many privately held AI start-ups.

Via The Motley Fool

3 AI Stocks Disrupting Trillion-Dollar Industries ↗

September 02, 2025

These three companies are using artificial intelligence (AI) to transform defense, pharmaceuticals, and banking.

Via The Motley Fool

Topics Artificial Intelligence Economy

If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today ↗

August 29, 2025

This AI company isn't yet living up to the hype.

Via The Motley Fool

Topics Artificial Intelligence

Recursion to Participate in Upcoming Investor Conferences

August 27, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Recursion Pharmaceuticals Earnings Preview ↗

August 04, 2025

Via Benzinga

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

July 29, 2025

Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST

From Recursion Pharmaceuticals

Via GlobeNewswire

Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn

August 27, 2025

The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell ↗

August 25, 2025

There might be better artificial intelligence (AI) stocks out there to buy.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode ↗

August 23, 2025

The artificial intelligence revolution is leaving no opportunity unaddressed.

Via The Motley Fool

Topics Artificial Intelligence

Why Recursion Pharmaceuticals Stock Caught a Cold This Week ↗

August 22, 2025

The few news items from and about the company weren't all that positive.

Via The Motley Fool

Topics Regulatory Compliance

Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial

August 12, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗

August 10, 2025

These companies are in the right place at the right time with the right products.

Via The Motley Fool

Topics Artificial Intelligence

Why Recursion Pharmaceuticals Stock Tanked on Tuesday ↗

August 05, 2025

It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

Via The Motley Fool

Recursion (RXRX) Q2 Revenue Jumps 33% ↗

August 05, 2025

Via The Motley Fool

Topics Artificial Intelligence

Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates ↗

August 05, 2025

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per share,...

Via Benzinga

Recursion Pharmaceuticals-A (NASDAQ:RXRX) Reports Mixed Q2 2025 Earnings: Revenue Beat but EPS Miss ↗

August 05, 2025

Recursion Pharmaceuticals (RXRX) reported mixed Q2 2025 results, beating revenue estimates with $19.22M but missing EPS at -$0.41. Shares rose 5.5% pre-market amid clinical progress and Sanofi...

Via Chartmill

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

August 05, 2025

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7)

From Recursion Pharmaceuticals

Via GlobeNewswire

The Dawn of Hyper-Personalization: How Generative AI is Reshaping Our Digital World

August 04, 2025

The digital landscape is undergoing a profound transformation as personalized AI, particularly generative AI models, are increasingly being fine-tuned to individual preferences and histories. This...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

2 Beaten-Down Stocks With Incredible Upside Potential ↗

August 03, 2025

Getting in on the ground floor with these companies might lead to superior returns.

Via The Motley Fool

Why Recursion Pharmaceuticals Stock Got Mashed on Monday ↗

July 28, 2025

Investors weren't cheered by news from one of the biotech's rivals.

Via The Motley Fool

The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades. ↗

July 26, 2025

You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.

Via The Motley Fool

Topics Artificial Intelligence Retirement

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills ↗

July 26, 2025

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

Via Benzinga

Topics Artificial Intelligence ETFs

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma ↗

July 25, 2025

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.

Via Benzinga

3 AI Stocks Partnered With Nvidia With Massive Growth Opportunities ↗

July 23, 2025

Via The Motley Fool

Topics Artificial Intelligence

Biocomputers: The Future of Computing is Alive

July 22, 2025

In the rapidly evolving world of technology, a groundbreaking frontier is emerging that could redefine the very nature of computation: biocomputers. Unlike traditional computers built from...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Recursion Pharmaceuticals Sees Sharp Gain on AI Biotech Optimism

July 22, 2025

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) experienced a notable surge in its stock price as investor enthusiasm for artificial intelligence-driven biotechnology reached new highs. The rally comes...

Via MarketMinute

Topics Artificial Intelligence

Top 2 Health Care Stocks You May Want To Dump This Quarter ↗

July 22, 2025

Via Benzinga

History of Recursion Pharmaceuticals, Inc.: AI‑Driven Drug Discovery Beginnings (NASDAQ:RXRX)

July 21, 2025

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) emerged in the 2010s as one of the pioneers in leveraging artificial intelligence (AI) and advanced data analytics to transform drug discovery and...

Via MarketMinute

Topics Artificial Intelligence

Is Recursion Pharmaceuticals Gaining or Losing Market Support? ↗

July 21, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.